Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Opioid-Related Disorders | 76 | 2024 | 465 | 17.330 |
Why?
|
Substance-Related Disorders | 80 | 2025 | 691 | 11.670 |
Why?
|
Buprenorphine | 32 | 2024 | 186 | 9.070 |
Why?
|
Narcotic Antagonists | 28 | 2024 | 114 | 6.750 |
Why?
|
Substance Abuse Treatment Centers | 34 | 2019 | 103 | 6.360 |
Why?
|
Opiate Substitution Treatment | 34 | 2024 | 192 | 6.300 |
Why?
|
Prisoners | 31 | 2024 | 166 | 5.800 |
Why?
|
Drug Overdose | 18 | 2025 | 120 | 5.580 |
Why?
|
Naltrexone | 21 | 2024 | 75 | 5.390 |
Why?
|
Substance Abuse, Intravenous | 28 | 2024 | 75 | 4.790 |
Why?
|
Rural Population | 17 | 2025 | 191 | 4.010 |
Why?
|
Alcoholism | 20 | 2022 | 307 | 3.840 |
Why?
|
Analgesics, Opioid | 25 | 2024 | 496 | 3.740 |
Why?
|
Hepatitis C | 9 | 2024 | 139 | 3.730 |
Why?
|
HIV Infections | 22 | 2025 | 921 | 3.580 |
Why?
|
Methadone | 29 | 2024 | 126 | 3.440 |
Why?
|
Patient Protection and Affordable Care Act | 10 | 2019 | 46 | 3.230 |
Why?
|
Medicaid | 10 | 2025 | 335 | 3.000 |
Why?
|
Health Services Accessibility | 16 | 2025 | 542 | 2.820 |
Why?
|
Humans | 265 | 2025 | 59495 | 2.810 |
Why?
|
Adult | 128 | 2025 | 15783 | 2.380 |
Why?
|
Insurance Coverage | 8 | 2025 | 98 | 2.380 |
Why?
|
United States | 79 | 2025 | 7511 | 2.380 |
Why?
|
Criminal Law | 9 | 2018 | 91 | 2.230 |
Why?
|
Male | 156 | 2025 | 27562 | 1.970 |
Why?
|
Female | 155 | 2025 | 30908 | 1.950 |
Why?
|
Patient Acceptance of Health Care | 11 | 2025 | 446 | 1.860 |
Why?
|
Prisons | 12 | 2024 | 114 | 1.790 |
Why?
|
Delayed-Action Preparations | 11 | 2024 | 105 | 1.720 |
Why?
|
Health Policy | 5 | 2024 | 185 | 1.710 |
Why?
|
Alcohol Drinking | 11 | 2022 | 299 | 1.690 |
Why?
|
Patient-Centered Care | 4 | 2020 | 248 | 1.590 |
Why?
|
Neonatal Abstinence Syndrome | 4 | 2020 | 33 | 1.570 |
Why?
|
Primary Health Care | 14 | 2017 | 647 | 1.540 |
Why?
|
Ambulatory Care | 11 | 2021 | 300 | 1.500 |
Why?
|
Needle-Exchange Programs | 10 | 2024 | 15 | 1.420 |
Why?
|
Drug Users | 7 | 2025 | 28 | 1.380 |
Why?
|
Needle Sharing | 6 | 2024 | 13 | 1.370 |
Why?
|
Emergency Service, Hospital | 9 | 2022 | 1023 | 1.360 |
Why?
|
Criminals | 7 | 2018 | 59 | 1.320 |
Why?
|
Secondary Prevention | 9 | 2017 | 153 | 1.300 |
Why?
|
Middle Aged | 74 | 2025 | 16275 | 1.300 |
Why?
|
State Government | 3 | 2019 | 32 | 1.280 |
Why?
|
Continuity of Patient Care | 6 | 2017 | 172 | 1.240 |
Why?
|
Mass Screening | 11 | 2023 | 647 | 1.230 |
Why?
|
Practice Patterns, Physicians' | 8 | 2023 | 715 | 1.220 |
Why?
|
Narcotics | 7 | 2012 | 50 | 1.210 |
Why?
|
Delivery of Health Care, Integrated | 5 | 2015 | 114 | 1.180 |
Why?
|
Health Knowledge, Attitudes, Practice | 9 | 2024 | 741 | 1.110 |
Why?
|
Substance Withdrawal Syndrome | 5 | 2024 | 117 | 1.070 |
Why?
|
Cataract Extraction | 3 | 2011 | 35 | 1.070 |
Why?
|
Massachusetts | 18 | 2024 | 2086 | 1.060 |
Why?
|
Telemedicine | 2 | 2024 | 335 | 1.030 |
Why?
|
Qualitative Research | 9 | 2024 | 609 | 1.010 |
Why?
|
Cross-Sectional Studies | 26 | 2024 | 2468 | 1.010 |
Why?
|
Hepacivirus | 5 | 2024 | 140 | 1.010 |
Why?
|
Referral and Consultation | 8 | 2024 | 409 | 1.000 |
Why?
|
New England | 9 | 2024 | 268 | 0.980 |
Why?
|
Medication Adherence | 2 | 2017 | 255 | 0.970 |
Why?
|
Postoperative Complications | 8 | 2011 | 1134 | 0.960 |
Why?
|
Attitude of Health Personnel | 8 | 2024 | 558 | 0.950 |
Why?
|
Delivery of Health Care | 4 | 2020 | 421 | 0.950 |
Why?
|
Mothers | 6 | 2023 | 261 | 0.920 |
Why?
|
Recidivism | 2 | 2022 | 26 | 0.910 |
Why?
|
Behavior, Addictive | 3 | 2014 | 75 | 0.900 |
Why?
|
Fentanyl | 1 | 2024 | 70 | 0.890 |
Why?
|
Sexual Partners | 5 | 2013 | 74 | 0.850 |
Why?
|
Early Medical Intervention | 2 | 2020 | 17 | 0.850 |
Why?
|
Surveys and Questionnaires | 23 | 2023 | 2592 | 0.850 |
Why?
|
Health Services Needs and Demand | 9 | 2015 | 214 | 0.840 |
Why?
|
Behavior Therapy | 3 | 2016 | 161 | 0.840 |
Why?
|
Pharmacies | 1 | 2023 | 36 | 0.820 |
Why?
|
Population Surveillance | 3 | 2019 | 205 | 0.790 |
Why?
|
Counseling | 8 | 2021 | 351 | 0.780 |
Why?
|
Inservice Training | 2 | 2017 | 83 | 0.780 |
Why?
|
Smoking Cessation | 7 | 2016 | 531 | 0.780 |
Why?
|
Harm Reduction | 3 | 2024 | 24 | 0.770 |
Why?
|
Injections, Intramuscular | 6 | 2020 | 69 | 0.770 |
Why?
|
Drug Monitoring | 2 | 2012 | 99 | 0.750 |
Why?
|
Naloxone | 6 | 2023 | 54 | 0.750 |
Why?
|
Substance Abuse Detection | 5 | 2009 | 39 | 0.740 |
Why?
|
Tobacco Use Disorder | 4 | 2014 | 245 | 0.730 |
Why?
|
Intimate Partner Violence | 1 | 2021 | 26 | 0.720 |
Why?
|
Sexual Behavior | 8 | 2025 | 183 | 0.710 |
Why?
|
Sleep Wake Disorders | 3 | 2008 | 68 | 0.700 |
Why?
|
Interinstitutional Relations | 2 | 2016 | 40 | 0.700 |
Why?
|
Intraoperative Complications | 2 | 2011 | 81 | 0.700 |
Why?
|
Alcohol-Related Disorders | 3 | 2021 | 36 | 0.690 |
Why?
|
Healthcare Disparities | 3 | 2024 | 330 | 0.680 |
Why?
|
Parents | 2 | 2023 | 379 | 0.680 |
Why?
|
Infant Health | 1 | 2019 | 2 | 0.670 |
Why?
|
Maternal Health | 1 | 2019 | 13 | 0.660 |
Why?
|
Surgical Procedures, Operative | 3 | 2012 | 139 | 0.660 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2020 | 73 | 0.660 |
Why?
|
Practice Patterns, Nurses' | 1 | 2019 | 19 | 0.650 |
Why?
|
Hospitalization | 7 | 2024 | 1282 | 0.650 |
Why?
|
Patient Dropouts | 5 | 2007 | 48 | 0.640 |
Why?
|
Equipment and Supplies, Hospital | 1 | 2019 | 4 | 0.640 |
Why?
|
Epidemics | 1 | 2019 | 22 | 0.640 |
Why?
|
Family Practice | 7 | 2005 | 204 | 0.640 |
Why?
|
Financing, Government | 1 | 2019 | 33 | 0.640 |
Why?
|
Young Adult | 16 | 2024 | 4329 | 0.630 |
Why?
|
Fear | 3 | 2024 | 64 | 0.620 |
Why?
|
HIV Seropositivity | 7 | 2012 | 82 | 0.620 |
Why?
|
Community Health Services | 4 | 2016 | 128 | 0.620 |
Why?
|
Veterans | 7 | 2014 | 723 | 0.610 |
Why?
|
Health Status | 5 | 2022 | 449 | 0.610 |
Why?
|
Government Programs | 1 | 2017 | 20 | 0.590 |
Why?
|
Cooperative Behavior | 4 | 2024 | 220 | 0.580 |
Why?
|
Rhode Island | 10 | 2013 | 97 | 0.580 |
Why?
|
Heroin Dependence | 5 | 2012 | 22 | 0.580 |
Why?
|
Models, Statistical | 3 | 2016 | 306 | 0.580 |
Why?
|
Multivariate Analysis | 13 | 2024 | 926 | 0.580 |
Why?
|
Quality of Life | 5 | 2020 | 1116 | 0.570 |
Why?
|
Aged | 40 | 2024 | 13339 | 0.570 |
Why?
|
General Surgery | 5 | 2001 | 186 | 0.560 |
Why?
|
Quality Assurance, Health Care | 2 | 2016 | 246 | 0.560 |
Why?
|
Patient Compliance | 7 | 2018 | 372 | 0.550 |
Why?
|
Informed Consent | 5 | 2018 | 133 | 0.550 |
Why?
|
Retrospective Studies | 21 | 2024 | 6008 | 0.540 |
Why?
|
Politics | 1 | 2017 | 31 | 0.540 |
Why?
|
Law Enforcement | 2 | 2013 | 27 | 0.540 |
Why?
|
Public Health | 2 | 2017 | 180 | 0.530 |
Why?
|
Data Collection | 12 | 2023 | 384 | 0.530 |
Why?
|
Aged, 80 and over | 19 | 2021 | 5089 | 0.520 |
Why?
|
Pharmacists | 3 | 2013 | 123 | 0.520 |
Why?
|
Health Resources | 1 | 2016 | 88 | 0.520 |
Why?
|
Anti-Anxiety Agents | 2 | 2008 | 31 | 0.520 |
Why?
|
Crime | 3 | 2012 | 63 | 0.510 |
Why?
|
Treatment Outcome | 18 | 2024 | 5183 | 0.510 |
Why?
|
Police | 1 | 2016 | 37 | 0.500 |
Why?
|
Hepatitis C, Chronic | 2 | 2013 | 88 | 0.500 |
Why?
|
State Health Plans | 1 | 2015 | 12 | 0.490 |
Why?
|
Resource Allocation | 1 | 2015 | 20 | 0.490 |
Why?
|
Health Care Rationing | 1 | 2015 | 21 | 0.490 |
Why?
|
Social Stigma | 7 | 2025 | 67 | 0.490 |
Why?
|
Prescriptions | 1 | 2015 | 33 | 0.490 |
Why?
|
Health Plan Implementation | 1 | 2015 | 42 | 0.480 |
Why?
|
Cohort Studies | 18 | 2024 | 2442 | 0.480 |
Why?
|
Longitudinal Studies | 10 | 2017 | 1225 | 0.480 |
Why?
|
Mental Health Services | 7 | 2020 | 299 | 0.480 |
Why?
|
Information Storage and Retrieval | 1 | 2015 | 79 | 0.470 |
Why?
|
Community Mental Health Services | 1 | 2016 | 104 | 0.470 |
Why?
|
Hindlimb | 4 | 2000 | 44 | 0.460 |
Why?
|
Mental Disorders | 7 | 2019 | 764 | 0.450 |
Why?
|
Evidence-Based Medicine | 3 | 2013 | 452 | 0.450 |
Why?
|
Blood Loss, Surgical | 2 | 2012 | 55 | 0.450 |
Why?
|
Syringes | 2 | 2024 | 11 | 0.450 |
Why?
|
Directly Observed Therapy | 1 | 2013 | 3 | 0.440 |
Why?
|
Fibroblast Growth Factor 2 | 3 | 2000 | 17 | 0.440 |
Why?
|
HIV Seronegativity | 4 | 2002 | 18 | 0.440 |
Why?
|
Prevalence | 11 | 2024 | 1281 | 0.430 |
Why?
|
Pharmaceutical Services | 2 | 2013 | 31 | 0.430 |
Why?
|
Physicians, Family | 5 | 2008 | 75 | 0.430 |
Why?
|
Interviews as Topic | 8 | 2024 | 486 | 0.430 |
Why?
|
Adolescent | 16 | 2023 | 5930 | 0.430 |
Why?
|
Patient Satisfaction | 3 | 2008 | 410 | 0.420 |
Why?
|
Methamphetamine | 2 | 2023 | 22 | 0.420 |
Why?
|
Prescription Drug Misuse | 1 | 2013 | 22 | 0.420 |
Why?
|
Blood Transfusion | 2 | 2012 | 148 | 0.420 |
Why?
|
Internet | 2 | 2015 | 458 | 0.420 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2012 | 9 | 0.410 |
Why?
|
Pilot Projects | 6 | 2022 | 919 | 0.410 |
Why?
|
Infant | 5 | 2021 | 1527 | 0.410 |
Why?
|
Residential Treatment | 3 | 2024 | 35 | 0.410 |
Why?
|
Needles | 1 | 2013 | 63 | 0.400 |
Why?
|
Risk-Taking | 10 | 2025 | 160 | 0.400 |
Why?
|
Cardiovascular Diseases | 7 | 2022 | 827 | 0.400 |
Why?
|
Health Personnel | 1 | 2016 | 341 | 0.400 |
Why?
|
Length of Stay | 5 | 2007 | 771 | 0.390 |
Why?
|
Prospective Studies | 15 | 2020 | 3101 | 0.390 |
Why?
|
Age Factors | 5 | 2017 | 1518 | 0.390 |
Why?
|
Logistic Models | 11 | 2019 | 1252 | 0.390 |
Why?
|
Hematocrit | 2 | 2010 | 33 | 0.370 |
Why?
|
Sexually Transmitted Diseases | 1 | 2012 | 93 | 0.370 |
Why?
|
Antiviral Agents | 3 | 2024 | 314 | 0.360 |
Why?
|
Prescription Drugs | 1 | 2011 | 50 | 0.360 |
Why?
|
Eye Diseases | 1 | 2011 | 37 | 0.360 |
Why?
|
Comorbidity | 8 | 2019 | 1090 | 0.360 |
Why?
|
Chronic Disease | 3 | 2010 | 735 | 0.360 |
Why?
|
Intraoperative Care | 1 | 2010 | 36 | 0.350 |
Why?
|
Pregnancy | 7 | 2021 | 2355 | 0.350 |
Why?
|
Rectal Neoplasms | 5 | 1996 | 97 | 0.340 |
Why?
|
Alcoholic Intoxication | 2 | 2017 | 27 | 0.330 |
Why?
|
Internship and Residency | 7 | 2002 | 723 | 0.330 |
Why?
|
Infant, Newborn | 6 | 2020 | 1311 | 0.330 |
Why?
|
Violence | 2 | 2009 | 149 | 0.330 |
Why?
|
Practice Guidelines as Topic | 5 | 2014 | 703 | 0.330 |
Why?
|
Quality of Health Care | 4 | 2012 | 519 | 0.320 |
Why?
|
Influenza Vaccines | 2 | 2014 | 88 | 0.320 |
Why?
|
Leadership | 2 | 2023 | 201 | 0.320 |
Why?
|
Patient Care Team | 2 | 2024 | 327 | 0.320 |
Why?
|
Psychiatry | 3 | 2005 | 129 | 0.320 |
Why?
|
Neovascularization, Physiologic | 2 | 2000 | 102 | 0.320 |
Why?
|
Trazodone | 1 | 2008 | 3 | 0.310 |
Why?
|
Databases, Factual | 4 | 2019 | 838 | 0.310 |
Why?
|
Child, Preschool | 5 | 2023 | 1839 | 0.310 |
Why?
|
Recurrence | 5 | 2017 | 578 | 0.310 |
Why?
|
Inpatients | 2 | 2024 | 296 | 0.300 |
Why?
|
Evidence-Based Practice | 2 | 2023 | 82 | 0.300 |
Why?
|
Health Care Surveys | 7 | 2013 | 279 | 0.300 |
Why?
|
Education, Medical, Continuing | 2 | 2006 | 98 | 0.300 |
Why?
|
Central Nervous System Depressants | 1 | 2008 | 42 | 0.300 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2008 | 17 | 0.300 |
Why?
|
Regression Analysis | 8 | 2011 | 484 | 0.290 |
Why?
|
Time Factors | 10 | 2017 | 3579 | 0.290 |
Why?
|
Polycythemia | 1 | 2007 | 4 | 0.290 |
Why?
|
Health Care Reform | 2 | 2019 | 88 | 0.290 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2022 | 668 | 0.280 |
Why?
|
Program Evaluation | 5 | 2019 | 484 | 0.280 |
Why?
|
Meningitis | 2 | 1998 | 18 | 0.280 |
Why?
|
Ischemia | 4 | 2000 | 192 | 0.280 |
Why?
|
Social Work | 2 | 2024 | 24 | 0.270 |
Why?
|
Hallucinogens | 1 | 2006 | 14 | 0.270 |
Why?
|
Outpatients | 3 | 2017 | 131 | 0.270 |
Why?
|
N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2006 | 18 | 0.270 |
Why?
|
Follow-Up Studies | 12 | 2017 | 2329 | 0.270 |
Why?
|
Social Security | 1 | 2006 | 7 | 0.260 |
Why?
|
Oxycodone | 1 | 2006 | 32 | 0.260 |
Why?
|
Pregnancy Complications | 3 | 2019 | 391 | 0.260 |
Why?
|
Antidepressive Agents | 2 | 2010 | 229 | 0.260 |
Why?
|
Preventive Health Services | 3 | 2012 | 72 | 0.260 |
Why?
|
Anemia | 1 | 2007 | 117 | 0.260 |
Why?
|
Case Management | 2 | 2004 | 61 | 0.260 |
Why?
|
Rehabilitation, Vocational | 1 | 2005 | 34 | 0.260 |
Why?
|
Internal Medicine | 5 | 2005 | 148 | 0.250 |
Why?
|
Risk Factors | 16 | 2012 | 5015 | 0.250 |
Why?
|
Health Surveys | 3 | 2006 | 306 | 0.250 |
Why?
|
Cocaine-Related Disorders | 1 | 2006 | 75 | 0.250 |
Why?
|
Patient Selection | 4 | 2024 | 446 | 0.250 |
Why?
|
Ethanol | 1 | 2008 | 307 | 0.240 |
Why?
|
United States Department of Veterans Affairs | 5 | 2014 | 513 | 0.240 |
Why?
|
Drug Utilization | 2 | 2005 | 223 | 0.240 |
Why?
|
Health Services for the Aged | 2 | 2004 | 48 | 0.240 |
Why?
|
Mobile Health Units | 1 | 2024 | 10 | 0.240 |
Why?
|
Surgery Department, Hospital | 2 | 1998 | 20 | 0.240 |
Why?
|
Hospitals, Community | 2 | 2019 | 71 | 0.240 |
Why?
|
Odds Ratio | 7 | 2014 | 773 | 0.230 |
Why?
|
Motivational Interviewing | 2 | 2022 | 42 | 0.230 |
Why?
|
Sex Factors | 7 | 2013 | 960 | 0.220 |
Why?
|
Comprehensive Health Care | 1 | 2004 | 18 | 0.220 |
Why?
|
Sex Work | 1 | 2023 | 21 | 0.220 |
Why?
|
Insurance, Health | 1 | 2025 | 141 | 0.220 |
Why?
|
Child | 4 | 2021 | 4304 | 0.220 |
Why?
|
Seroepidemiologic Studies | 2 | 2023 | 48 | 0.220 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 97 | 0.220 |
Why?
|
Health Behavior | 3 | 2002 | 473 | 0.220 |
Why?
|
Medically Uninsured | 2 | 2019 | 40 | 0.210 |
Why?
|
Disabled Persons | 1 | 2006 | 205 | 0.210 |
Why?
|
Mental Processes | 1 | 2023 | 18 | 0.210 |
Why?
|
Vascular Surgical Procedures | 4 | 1993 | 245 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2012 | 809 | 0.210 |
Why?
|
Connecticut | 2 | 2013 | 86 | 0.210 |
Why?
|
Hypnotics and Sedatives | 1 | 2003 | 71 | 0.200 |
Why?
|
Preoperative Care | 4 | 2007 | 175 | 0.200 |
Why?
|
Federal Government | 2 | 2017 | 20 | 0.200 |
Why?
|
Prescription Drug Diversion | 1 | 2022 | 7 | 0.200 |
Why?
|
Drug Utilization Review | 2 | 1999 | 56 | 0.200 |
Why?
|
Mandatory Reporting | 1 | 2002 | 18 | 0.200 |
Why?
|
Friends | 1 | 2022 | 29 | 0.190 |
Why?
|
Vaccination | 1 | 2004 | 337 | 0.190 |
Why?
|
Influenza, Human | 1 | 2004 | 193 | 0.190 |
Why?
|
Domestic Violence | 1 | 2002 | 35 | 0.190 |
Why?
|
Safe Sex | 1 | 2001 | 25 | 0.190 |
Why?
|
Transportation of Patients | 1 | 2001 | 42 | 0.180 |
Why?
|
Binge Drinking | 1 | 2021 | 29 | 0.180 |
Why?
|
Guideline Adherence | 4 | 2014 | 296 | 0.180 |
Why?
|
Hospitals, Teaching | 3 | 2002 | 103 | 0.180 |
Why?
|
Health Services Research | 4 | 2013 | 270 | 0.180 |
Why?
|
Medical History Taking | 1 | 2001 | 58 | 0.180 |
Why?
|
Activities of Daily Living | 2 | 1999 | 298 | 0.180 |
Why?
|
Endarterectomy | 4 | 1989 | 17 | 0.180 |
Why?
|
Coercion | 2 | 2016 | 53 | 0.180 |
Why?
|
Smoking | 3 | 2014 | 830 | 0.180 |
Why?
|
Guilt | 1 | 2020 | 7 | 0.170 |
Why?
|
Shame | 1 | 2020 | 8 | 0.170 |
Why?
|
Cocaine | 4 | 2012 | 86 | 0.170 |
Why?
|
Linear Models | 5 | 2012 | 422 | 0.170 |
Why?
|
Judgment | 1 | 2020 | 30 | 0.170 |
Why?
|
Mortality | 1 | 2001 | 159 | 0.170 |
Why?
|
Needs Assessment | 1 | 2001 | 188 | 0.170 |
Why?
|
Hospitals, Veterans | 2 | 2012 | 159 | 0.170 |
Why?
|
Feasibility Studies | 5 | 2013 | 524 | 0.170 |
Why?
|
Sickness Impact Profile | 1 | 1999 | 46 | 0.170 |
Why?
|
Ambulatory Care Facilities | 1 | 2000 | 102 | 0.170 |
Why?
|
Health Equity | 1 | 2020 | 42 | 0.170 |
Why?
|
Vermont | 1 | 2019 | 17 | 0.170 |
Why?
|
Emergencies | 2 | 1999 | 114 | 0.170 |
Why?
|
Cost Allocation | 1 | 2019 | 3 | 0.160 |
Why?
|
Sensitivity and Specificity | 5 | 2024 | 1095 | 0.160 |
Why?
|
New Hampshire | 1 | 2019 | 42 | 0.160 |
Why?
|
Graft Survival | 2 | 2017 | 279 | 0.160 |
Why?
|
Risk Assessment | 4 | 2011 | 1914 | 0.160 |
Why?
|
Statistics as Topic | 4 | 2014 | 147 | 0.160 |
Why?
|
Professional-Patient Relations | 1 | 2020 | 127 | 0.160 |
Why?
|
Carotid Arteries | 2 | 1989 | 59 | 0.160 |
Why?
|
Postpartum Period | 1 | 2021 | 203 | 0.160 |
Why?
|
Medication Errors | 1 | 1999 | 116 | 0.160 |
Why?
|
Pandemics | 2 | 2021 | 608 | 0.160 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 1995 | 67 | 0.160 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2019 | 31 | 0.160 |
Why?
|
Analysis of Variance | 8 | 2008 | 576 | 0.160 |
Why?
|
Central Nervous System Stimulants | 2 | 2024 | 63 | 0.150 |
Why?
|
Maternal Health Services | 1 | 2019 | 64 | 0.150 |
Why?
|
Communication | 2 | 2023 | 554 | 0.150 |
Why?
|
Betacoronavirus | 1 | 2020 | 160 | 0.150 |
Why?
|
Focus Groups | 1 | 2020 | 291 | 0.150 |
Why?
|
Buprenorphine, Naloxone Drug Combination | 3 | 2013 | 26 | 0.150 |
Why?
|
Decision Making | 2 | 2019 | 390 | 0.150 |
Why?
|
Health Insurance Exchanges | 1 | 2017 | 1 | 0.150 |
Why?
|
Digestive System Surgical Procedures | 1 | 2019 | 87 | 0.150 |
Why?
|
Interprofessional Relations | 2 | 2012 | 131 | 0.150 |
Why?
|
Obstetrics and Gynecology Department, Hospital | 1 | 1998 | 11 | 0.150 |
Why?
|
Breast Feeding | 1 | 2020 | 138 | 0.150 |
Why?
|
Pain Management | 1 | 2019 | 145 | 0.150 |
Why?
|
Transportation | 3 | 2024 | 33 | 0.150 |
Why?
|
Risk Management | 1 | 1998 | 39 | 0.150 |
Why?
|
Cardiac Surgical Procedures | 1 | 2021 | 249 | 0.150 |
Why?
|
Polytetrafluoroethylene | 1 | 1997 | 18 | 0.140 |
Why?
|
Psychotic Disorders | 2 | 2012 | 151 | 0.140 |
Why?
|
Public Policy | 1 | 2018 | 41 | 0.140 |
Why?
|
Cardiology | 2 | 1997 | 165 | 0.140 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2014 | 142 | 0.140 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 1998 | 195 | 0.140 |
Why?
|
Patient Preference | 1 | 2018 | 76 | 0.140 |
Why?
|
Coronavirus Infections | 1 | 2020 | 187 | 0.140 |
Why?
|
Patient Participation | 1 | 2019 | 211 | 0.140 |
Why?
|
Donor Selection | 1 | 2017 | 16 | 0.140 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 199 | 0.140 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 1997 | 42 | 0.140 |
Why?
|
Survival Rate | 3 | 2019 | 791 | 0.140 |
Why?
|
Wounds and Injuries | 1 | 1999 | 237 | 0.140 |
Why?
|
Urban Population | 7 | 2008 | 182 | 0.140 |
Why?
|
Schizophrenia | 2 | 2012 | 256 | 0.140 |
Why?
|
Patient Care Management | 1 | 2017 | 29 | 0.140 |
Why?
|
Combined Modality Therapy | 5 | 1999 | 355 | 0.140 |
Why?
|
Physician's Role | 1 | 1998 | 119 | 0.140 |
Why?
|
Surgical Wound Infection | 1 | 1998 | 108 | 0.140 |
Why?
|
Patient Readmission | 1 | 2001 | 420 | 0.140 |
Why?
|
Organizational Innovation | 1 | 2017 | 85 | 0.130 |
Why?
|
Bipolar Disorder | 2 | 2012 | 254 | 0.130 |
Why?
|
Cross Infection | 1 | 1998 | 151 | 0.130 |
Why?
|
Diabetic Angiopathies | 3 | 2009 | 25 | 0.130 |
Why?
|
Incidence | 5 | 2011 | 1237 | 0.130 |
Why?
|
Chicago | 3 | 2001 | 24 | 0.130 |
Why?
|
Organizations | 1 | 2016 | 6 | 0.130 |
Why?
|
Clinical Protocols | 1 | 2017 | 134 | 0.130 |
Why?
|
Social Support | 2 | 2013 | 358 | 0.130 |
Why?
|
Biocompatible Materials | 1 | 1997 | 140 | 0.130 |
Why?
|
Postoperative Care | 1 | 1996 | 112 | 0.130 |
Why?
|
Diabetes Complications | 2 | 2011 | 102 | 0.130 |
Why?
|
Human Experimentation | 1 | 2016 | 33 | 0.130 |
Why?
|
Renal Dialysis | 1 | 1997 | 185 | 0.130 |
Why?
|
Contract Services | 1 | 2015 | 2 | 0.130 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 299 | 0.130 |
Why?
|
Endarterectomy, Carotid | 1 | 1996 | 87 | 0.130 |
Why?
|
Patient Education as Topic | 3 | 2014 | 446 | 0.130 |
Why?
|
Neovascularization, Pathologic | 2 | 1995 | 138 | 0.120 |
Why?
|
Patient Admission | 1 | 2017 | 185 | 0.120 |
Why?
|
Methylprednisolone | 1 | 1995 | 31 | 0.120 |
Why?
|
Risk Reduction Behavior | 2 | 2006 | 125 | 0.120 |
Why?
|
Body Weight | 1 | 2017 | 378 | 0.120 |
Why?
|
Intersectoral Collaboration | 1 | 2015 | 17 | 0.120 |
Why?
|
Carcinoma | 2 | 1987 | 117 | 0.120 |
Why?
|
Spinal Cord Injuries | 1 | 1995 | 38 | 0.120 |
Why?
|
Community-Institutional Relations | 1 | 2015 | 37 | 0.120 |
Why?
|
Fibroblast Growth Factors | 1 | 1995 | 63 | 0.120 |
Why?
|
Survival Analysis | 4 | 2012 | 553 | 0.120 |
Why?
|
Safety-net Providers | 1 | 2015 | 34 | 0.120 |
Why?
|
Taurine | 1 | 2014 | 5 | 0.120 |
Why?
|
Disulfiram | 1 | 2014 | 4 | 0.120 |
Why?
|
Acquired Immunodeficiency Syndrome | 5 | 1996 | 137 | 0.120 |
Why?
|
Kidney Transplantation | 1 | 2017 | 266 | 0.120 |
Why?
|
Pneumococcal Vaccines | 1 | 2014 | 19 | 0.120 |
Why?
|
Directive Counseling | 1 | 2014 | 39 | 0.120 |
Why?
|
Elective Surgical Procedures | 2 | 2022 | 104 | 0.120 |
Why?
|
Aftercare | 2 | 2022 | 67 | 0.120 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 442 | 0.110 |
Why?
|
Spinal Cord | 1 | 1995 | 197 | 0.110 |
Why?
|
Accountable Care Organizations | 1 | 2015 | 57 | 0.110 |
Why?
|
Recombinant Proteins | 2 | 2013 | 694 | 0.110 |
Why?
|
Housing | 2 | 2024 | 72 | 0.110 |
Why?
|
Smoking Prevention | 2 | 2013 | 162 | 0.110 |
Why?
|
Smoke-Free Policy | 1 | 2013 | 9 | 0.110 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2014 | 63 | 0.110 |
Why?
|
Staff Development | 2 | 2007 | 56 | 0.110 |
Why?
|
History, 19th Century | 3 | 2001 | 42 | 0.110 |
Why?
|
Tobacco Products | 1 | 2014 | 75 | 0.110 |
Why?
|
Ribavirin | 1 | 2013 | 24 | 0.110 |
Why?
|
Education, Pharmacy, Continuing | 1 | 2013 | 3 | 0.110 |
Why?
|
Diffusion of Innovation | 1 | 2013 | 56 | 0.110 |
Why?
|
Personal Autonomy | 1 | 2013 | 66 | 0.110 |
Why?
|
Interferon-alpha | 1 | 2013 | 98 | 0.110 |
Why?
|
Collateral Circulation | 1 | 1992 | 22 | 0.100 |
Why?
|
Viral Load | 1 | 2013 | 229 | 0.100 |
Why?
|
History, 20th Century | 3 | 2001 | 225 | 0.100 |
Why?
|
Specialization | 2 | 2005 | 73 | 0.100 |
Why?
|
Electronic Prescribing | 1 | 2012 | 11 | 0.100 |
Why?
|
Physician-Patient Relations | 3 | 2002 | 388 | 0.100 |
Why?
|
Polyethylene Glycols | 1 | 2013 | 162 | 0.100 |
Why?
|
Program Development | 3 | 2008 | 210 | 0.100 |
Why?
|
Administration, Oral | 1 | 2013 | 344 | 0.100 |
Why?
|
Total Quality Management | 1 | 1992 | 58 | 0.100 |
Why?
|
Blood Coagulation | 1 | 2012 | 50 | 0.100 |
Why?
|
Lens Capsule, Crystalline | 1 | 2011 | 3 | 0.090 |
Why?
|
Cause of Death | 1 | 2012 | 200 | 0.090 |
Why?
|
Lacerations | 1 | 2011 | 16 | 0.090 |
Why?
|
Interview, Psychological | 2 | 2009 | 77 | 0.090 |
Why?
|
Tuberculosis | 3 | 2000 | 262 | 0.090 |
Why?
|
Intensive Care Units | 2 | 1996 | 449 | 0.090 |
Why?
|
Mandatory Programs | 1 | 2011 | 19 | 0.090 |
Why?
|
Reproducibility of Results | 4 | 2013 | 1551 | 0.090 |
Why?
|
Adenocarcinoma | 2 | 1988 | 323 | 0.090 |
Why?
|
Hospital Mortality | 2 | 2014 | 846 | 0.090 |
Why?
|
Vitreous Body | 1 | 2011 | 31 | 0.090 |
Why?
|
Cataract | 1 | 2011 | 54 | 0.090 |
Why?
|
Accreditation | 2 | 2007 | 69 | 0.090 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 123 | 0.090 |
Why?
|
Hospital Departments | 1 | 1990 | 13 | 0.090 |
Why?
|
Crack Cocaine | 3 | 1997 | 7 | 0.090 |
Why?
|
Streptonigrin | 1 | 2010 | 3 | 0.090 |
Why?
|
Erectile Dysfunction | 1 | 2010 | 22 | 0.090 |
Why?
|
Hospitals, University | 2 | 2001 | 50 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2012 | 147 | 0.090 |
Why?
|
Citalopram | 1 | 2010 | 17 | 0.090 |
Why?
|
Heart Failure | 2 | 2014 | 867 | 0.090 |
Why?
|
Socioeconomic Factors | 4 | 2019 | 781 | 0.090 |
Why?
|
Double-Blind Method | 2 | 2010 | 680 | 0.090 |
Why?
|
Postoperative Period | 1 | 2010 | 125 | 0.090 |
Why?
|
Medicine | 1 | 1990 | 56 | 0.090 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 900 | 0.090 |
Why?
|
Testosterone | 1 | 2010 | 111 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 282 | 0.090 |
Why?
|
Periodicals as Topic | 1 | 2012 | 173 | 0.090 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2012 | 220 | 0.080 |
Why?
|
Tuberculin Test | 2 | 2000 | 10 | 0.080 |
Why?
|
Models, Organizational | 3 | 2015 | 92 | 0.080 |
Why?
|
Long-Term Care | 1 | 2010 | 174 | 0.080 |
Why?
|
Appointments and Schedules | 1 | 2009 | 53 | 0.080 |
Why?
|
Unsafe Sex | 1 | 2009 | 27 | 0.080 |
Why?
|
Monitoring, Physiologic | 1 | 1990 | 150 | 0.080 |
Why?
|
Proportional Hazards Models | 4 | 2012 | 673 | 0.080 |
Why?
|
Hemodynamics | 1 | 1990 | 236 | 0.080 |
Why?
|
Skin | 3 | 2006 | 353 | 0.080 |
Why?
|
Inactivation, Metabolic | 1 | 2008 | 13 | 0.080 |
Why?
|
Macular Degeneration | 1 | 2011 | 176 | 0.080 |
Why?
|
New York City | 9 | 2000 | 75 | 0.080 |
Why?
|
Internal-External Control | 1 | 2008 | 32 | 0.070 |
Why?
|
Verbal Behavior | 1 | 2008 | 37 | 0.070 |
Why?
|
AIDS Serodiagnosis | 2 | 2002 | 19 | 0.070 |
Why?
|
Antisocial Personality Disorder | 1 | 2008 | 35 | 0.070 |
Why?
|
HIV Seroprevalence | 3 | 1996 | 7 | 0.070 |
Why?
|
Radiation Injuries | 1 | 1988 | 56 | 0.070 |
Why?
|
Societies, Medical | 2 | 2001 | 330 | 0.070 |
Why?
|
Blood Gas Monitoring, Transcutaneous | 2 | 2000 | 4 | 0.070 |
Why?
|
Intestine, Large | 1 | 1987 | 5 | 0.070 |
Why?
|
Life Tables | 2 | 1997 | 24 | 0.070 |
Why?
|
Cost Control | 1 | 2007 | 23 | 0.070 |
Why?
|
Community Networks | 1 | 2007 | 29 | 0.070 |
Why?
|
Clinical Competence | 3 | 2002 | 678 | 0.070 |
Why?
|
Professional Practice | 1 | 2006 | 22 | 0.070 |
Why?
|
Educational Status | 1 | 2008 | 271 | 0.070 |
Why?
|
Drug Prescriptions | 2 | 2006 | 188 | 0.070 |
Why?
|
Risk | 1 | 2007 | 372 | 0.070 |
Why?
|
Rabbits | 2 | 2000 | 330 | 0.070 |
Why?
|
Confidence Intervals | 2 | 2011 | 256 | 0.070 |
Why?
|
Drug Interactions | 2 | 2012 | 115 | 0.070 |
Why?
|
Medical Records | 1 | 2006 | 138 | 0.070 |
Why?
|
Organizational Culture | 1 | 2007 | 112 | 0.070 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2006 | 36 | 0.070 |
Why?
|
Eligibility Determination | 1 | 2006 | 34 | 0.070 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2006 | 8 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 196 | 0.060 |
Why?
|
Confidentiality | 2 | 2003 | 52 | 0.060 |
Why?
|
Cues | 1 | 2006 | 76 | 0.060 |
Why?
|
Medical Audit | 1 | 2006 | 60 | 0.060 |
Why?
|
Attitude to Health | 1 | 2008 | 275 | 0.060 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2006 | 51 | 0.060 |
Why?
|
Rats, Sprague-Dawley | 2 | 1998 | 570 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 387 | 0.060 |
Why?
|
Sleep Stages | 1 | 2005 | 16 | 0.060 |
Why?
|
Injections | 2 | 2018 | 79 | 0.060 |
Why?
|
Arterial Occlusive Diseases | 2 | 1976 | 68 | 0.060 |
Why?
|
Specialties, Surgical | 2 | 1999 | 44 | 0.060 |
Why?
|
Depression | 2 | 2010 | 857 | 0.060 |
Why?
|
Plant Preparations | 1 | 2005 | 16 | 0.060 |
Why?
|
Women's Health | 1 | 2008 | 390 | 0.060 |
Why?
|
Gynecology | 2 | 2005 | 52 | 0.060 |
Why?
|
Mucin-1 | 1 | 2004 | 14 | 0.060 |
Why?
|
Epidermolysis Bullosa | 1 | 2004 | 10 | 0.060 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2009 | 78 | 0.060 |
Why?
|
Disability Evaluation | 1 | 2006 | 216 | 0.060 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2005 | 47 | 0.060 |
Why?
|
Muscle, Skeletal | 2 | 2000 | 674 | 0.060 |
Why?
|
Sleep Apnea Syndromes | 1 | 2005 | 27 | 0.060 |
Why?
|
Femoral Artery | 3 | 1988 | 93 | 0.060 |
Why?
|
Cannabinoids | 1 | 2005 | 35 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 3 | 1996 | 301 | 0.060 |
Why?
|
Gender Identity | 1 | 2025 | 61 | 0.060 |
Why?
|
Phytotherapy | 1 | 2005 | 52 | 0.060 |
Why?
|
Sampling Studies | 1 | 2024 | 66 | 0.060 |
Why?
|
Hepatitis C Antibodies | 1 | 2024 | 8 | 0.060 |
Why?
|
Popliteal Artery | 2 | 1976 | 25 | 0.060 |
Why?
|
Cannabis | 1 | 2005 | 47 | 0.060 |
Why?
|
Decision Trees | 1 | 2003 | 51 | 0.060 |
Why?
|
Obstetrics | 2 | 2005 | 85 | 0.060 |
Why?
|
Uncompensated Care | 1 | 2003 | 5 | 0.050 |
Why?
|
Refusal to Treat | 1 | 2003 | 3 | 0.050 |
Why?
|
Laboratories, Hospital | 1 | 2003 | 9 | 0.050 |
Why?
|
Halfway Houses | 1 | 2003 | 2 | 0.050 |
Why?
|
False Positive Reactions | 1 | 2003 | 74 | 0.050 |
Why?
|
Sexual and Gender Minorities | 1 | 2025 | 73 | 0.050 |
Why?
|
Waiting Lists | 1 | 2003 | 48 | 0.050 |
Why?
|
Rats | 2 | 1998 | 1912 | 0.050 |
Why?
|
Attitude | 1 | 2023 | 100 | 0.050 |
Why?
|
Convalescence | 1 | 2003 | 17 | 0.050 |
Why?
|
Schools, Medical | 2 | 2001 | 144 | 0.050 |
Why?
|
Community Mental Health Centers | 1 | 2003 | 18 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2011 | 1449 | 0.050 |
Why?
|
House Calls | 1 | 2023 | 18 | 0.050 |
Why?
|
Depressive Disorder, Major | 1 | 2006 | 258 | 0.050 |
Why?
|
Phylogeny | 1 | 2024 | 332 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2004 | 353 | 0.050 |
Why?
|
Coronary Artery Disease | 1 | 2006 | 277 | 0.050 |
Why?
|
Occupational Health Services | 1 | 2003 | 39 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2009 | 674 | 0.050 |
Why?
|
Managed Care Programs | 1 | 2003 | 93 | 0.050 |
Why?
|
Grounded Theory | 1 | 2022 | 15 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2004 | 277 | 0.050 |
Why?
|
Habits | 1 | 2022 | 21 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2004 | 233 | 0.050 |
Why?
|
Interpersonal Relations | 2 | 2001 | 150 | 0.050 |
Why?
|
Parenting | 1 | 2023 | 73 | 0.050 |
Why?
|
Geriatric Assessment | 1 | 2003 | 161 | 0.050 |
Why?
|
Workplace | 1 | 2003 | 180 | 0.050 |
Why?
|
Curriculum | 1 | 2005 | 550 | 0.050 |
Why?
|
Crisis Intervention | 1 | 2002 | 28 | 0.050 |
Why?
|
Animals | 6 | 2000 | 19648 | 0.050 |
Why?
|
Job Satisfaction | 1 | 2002 | 134 | 0.050 |
Why?
|
Hospitals, Urban | 1 | 2001 | 44 | 0.050 |
Why?
|
Episode of Care | 1 | 2001 | 9 | 0.050 |
Why?
|
Poverty Areas | 1 | 2001 | 16 | 0.050 |
Why?
|
Genomics | 1 | 2024 | 314 | 0.050 |
Why?
|
Poverty | 1 | 2003 | 286 | 0.050 |
Why?
|
Specialty Boards | 2 | 1990 | 12 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2003 | 314 | 0.040 |
Why?
|
Factor Analysis, Statistical | 2 | 2013 | 104 | 0.040 |
Why?
|
Neoplasm Staging | 2 | 1996 | 454 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2001 | 113 | 0.040 |
Why?
|
Regional Blood Flow | 1 | 2000 | 108 | 0.040 |
Why?
|
Certification | 2 | 1990 | 49 | 0.040 |
Why?
|
Quality Indicators, Health Care | 2 | 2014 | 328 | 0.040 |
Why?
|
Cardiac Rehabilitation | 1 | 2021 | 67 | 0.040 |
Why?
|
Nurses | 1 | 2021 | 103 | 0.040 |
Why?
|
Faculty, Medical | 1 | 2002 | 203 | 0.040 |
Why?
|
Peptic Ulcer | 1 | 1999 | 21 | 0.040 |
Why?
|
Research Design | 3 | 2011 | 565 | 0.040 |
Why?
|
Radiotherapy Dosage | 2 | 1996 | 79 | 0.040 |
Why?
|
Respiratory Tract Diseases | 1 | 1999 | 35 | 0.040 |
Why?
|
Histamine Antagonists | 1 | 1999 | 5 | 0.040 |
Why?
|
Psychometrics | 2 | 2014 | 356 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2003 | 249 | 0.040 |
Why?
|
Morbidity | 1 | 1999 | 109 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2004 | 404 | 0.040 |
Why?
|
Diabetes Mellitus | 2 | 2006 | 537 | 0.040 |
Why?
|
Physicians | 2 | 2021 | 436 | 0.040 |
Why?
|
Perioperative Period | 1 | 2019 | 20 | 0.040 |
Why?
|
Streptozocin | 1 | 1998 | 20 | 0.040 |
Why?
|
Patient Discharge | 1 | 2022 | 479 | 0.040 |
Why?
|
Hospital Bed Capacity, 500 and over | 1 | 1998 | 8 | 0.040 |
Why?
|
Likelihood Functions | 1 | 1998 | 73 | 0.040 |
Why?
|
Accidental Falls | 1 | 1999 | 145 | 0.040 |
Why?
|
Self-Help Groups | 1 | 1998 | 37 | 0.040 |
Why?
|
Income | 1 | 2019 | 160 | 0.040 |
Why?
|
Forearm | 1 | 1997 | 19 | 0.040 |
Why?
|
AIDS Vaccines | 1 | 1997 | 67 | 0.040 |
Why?
|
Residence Characteristics | 2 | 2015 | 224 | 0.040 |
Why?
|
Angiography | 2 | 1974 | 145 | 0.030 |
Why?
|
Vascular Patency | 1 | 1997 | 134 | 0.030 |
Why?
|
Benchmarking | 1 | 1998 | 135 | 0.030 |
Why?
|
Radioisotope Teletherapy | 1 | 1996 | 1 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 1995 | 2069 | 0.030 |
Why?
|
Cobalt Radioisotopes | 1 | 1996 | 5 | 0.030 |
Why?
|
Spermatozoa | 1 | 1998 | 251 | 0.030 |
Why?
|
Thailand | 5 | 1995 | 94 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 1999 | 306 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 1996 | 104 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1996 | 61 | 0.030 |
Why?
|
Anemia, Sickle Cell | 1 | 1997 | 66 | 0.030 |
Why?
|
Mental Health | 1 | 1999 | 348 | 0.030 |
Why?
|
Condoms | 2 | 1993 | 47 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 1996 | 35 | 0.030 |
Why?
|
Angina Pectoris | 1 | 1996 | 36 | 0.030 |
Why?
|
Heroin | 2 | 1997 | 12 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 1978 | 213 | 0.030 |
Why?
|
Hospital Costs | 1 | 1997 | 120 | 0.030 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 1995 | 4 | 0.030 |
Why?
|
Saphenous Vein | 2 | 1976 | 43 | 0.030 |
Why?
|
Spinal Puncture | 1 | 1995 | 13 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 1996 | 233 | 0.030 |
Why?
|
Safety | 1 | 1996 | 141 | 0.030 |
Why?
|
Economic Competition | 1 | 2015 | 8 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 1996 | 68 | 0.030 |
Why?
|
Ownership | 1 | 2015 | 17 | 0.030 |
Why?
|
Systems Integration | 1 | 2015 | 27 | 0.030 |
Why?
|
Behavior | 1 | 1995 | 38 | 0.030 |
Why?
|
Drug Synergism | 1 | 1995 | 133 | 0.030 |
Why?
|
Case-Control Studies | 1 | 1998 | 1063 | 0.030 |
Why?
|
Rats, Wistar | 1 | 1995 | 179 | 0.030 |
Why?
|
Antitubercular Agents | 1 | 1995 | 77 | 0.030 |
Why?
|
Coronary Disease | 1 | 1996 | 250 | 0.030 |
Why?
|
Psychomotor Performance | 1 | 1995 | 133 | 0.030 |
Why?
|
Blood Vessel Prosthesis | 2 | 1976 | 209 | 0.030 |
Why?
|
Movement | 1 | 1995 | 146 | 0.030 |
Why?
|
Coronary Artery Bypass | 1 | 1996 | 274 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 1995 | 436 | 0.030 |
Why?
|
Hospitals | 1 | 1997 | 376 | 0.030 |
Why?
|
History, 18th Century | 1 | 1993 | 8 | 0.030 |
Why?
|
History, Ancient | 1 | 1993 | 11 | 0.030 |
Why?
|
Health Facility Administrators | 1 | 2013 | 7 | 0.030 |
Why?
|
Motivation | 1 | 2016 | 266 | 0.030 |
Why?
|
Didanosine | 1 | 1992 | 3 | 0.030 |
Why?
|
Zidovudine | 1 | 1992 | 12 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2014 | 160 | 0.030 |
Why?
|
Personnel Staffing and Scheduling | 1 | 1993 | 71 | 0.030 |
Why?
|
Tetrazolium Salts | 1 | 1992 | 15 | 0.030 |
Why?
|
Spectrophotometry | 1 | 1992 | 31 | 0.030 |
Why?
|
Ligation | 1 | 1992 | 35 | 0.030 |
Why?
|
Washington | 1 | 2012 | 25 | 0.030 |
Why?
|
Ventricular Function, Left | 1 | 2014 | 263 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2012 | 94 | 0.030 |
Why?
|
Drug Combinations | 1 | 2012 | 140 | 0.030 |
Why?
|
Prothrombin Time | 1 | 2012 | 6 | 0.020 |
Why?
|
Partial Thromboplastin Time | 1 | 2012 | 8 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2015 | 352 | 0.020 |
Why?
|
Contrast Media | 1 | 1974 | 410 | 0.020 |
Why?
|
Lymphatic Metastasis | 2 | 1985 | 71 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2012 | 70 | 0.020 |
Why?
|
Bevacizumab | 1 | 2012 | 57 | 0.020 |
Why?
|
Risk Adjustment | 1 | 2012 | 91 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2012 | 98 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 1992 | 59 | 0.020 |
Why?
|
Health Education | 2 | 2008 | 184 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 1 | 1990 | 24 | 0.020 |
Why?
|
Radiography | 1 | 1992 | 506 | 0.020 |
Why?
|
Cardiac Output | 1 | 1990 | 34 | 0.020 |
Why?
|
Vascular Resistance | 1 | 1990 | 44 | 0.020 |
Why?
|
Acute Disease | 1 | 1992 | 659 | 0.020 |
Why?
|
Surgery, Plastic | 1 | 1990 | 13 | 0.020 |
Why?
|
Hypertension | 1 | 1996 | 601 | 0.020 |
Why?
|
Teaching | 1 | 1990 | 154 | 0.020 |
Why?
|
Thoracic Surgery | 1 | 1990 | 66 | 0.020 |
Why?
|
National Institute on Drug Abuse (U.S.) | 1 | 2009 | 2 | 0.020 |
Why?
|
Coumarins | 1 | 1988 | 7 | 0.020 |
Why?
|
HIV-1 | 1 | 1994 | 708 | 0.020 |
Why?
|
Educational Measurement | 1 | 1990 | 207 | 0.020 |
Why?
|
Iodine Isotopes | 1 | 1968 | 2 | 0.020 |
Why?
|
Hyperthyroidism | 1 | 1968 | 17 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 1988 | 72 | 0.020 |
Why?
|
Financial Support | 1 | 2008 | 4 | 0.020 |
Why?
|
Necrosis | 1 | 1988 | 138 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 1988 | 53 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2003 | 1031 | 0.020 |
Why?
|
Psychology | 1 | 2008 | 47 | 0.020 |
Why?
|
Renal Veins | 1 | 1987 | 6 | 0.020 |
Why?
|
Heparin | 1 | 1988 | 113 | 0.020 |
Why?
|
Demography | 1 | 2008 | 178 | 0.020 |
Why?
|
Pediatrics | 1 | 1990 | 266 | 0.020 |
Why?
|
Lipids | 1 | 2009 | 306 | 0.020 |
Why?
|
Aorta, Abdominal | 1 | 1987 | 59 | 0.020 |
Why?
|
Heart Diseases | 1 | 2009 | 204 | 0.020 |
Why?
|
Surgical Staplers | 1 | 1987 | 6 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 1988 | 97 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 1988 | 196 | 0.020 |
Why?
|
Arteriovenous Fistula | 1 | 1987 | 39 | 0.020 |
Why?
|
Colostomy | 1 | 1987 | 23 | 0.020 |
Why?
|
Health Promotion | 1 | 2011 | 491 | 0.020 |
Why?
|
Universities | 1 | 2008 | 152 | 0.020 |
Why?
|
Suture Techniques | 1 | 1987 | 84 | 0.020 |
Why?
|
Celecoxib | 1 | 2006 | 14 | 0.020 |
Why?
|
England | 1 | 2006 | 21 | 0.020 |
Why?
|
Lactones | 1 | 2006 | 25 | 0.020 |
Why?
|
Sulfones | 1 | 2006 | 37 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2006 | 78 | 0.020 |
Why?
|
Students | 1 | 2008 | 207 | 0.020 |
Why?
|
Dogs | 1 | 1987 | 317 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2006 | 105 | 0.020 |
Why?
|
Permissiveness | 1 | 2005 | 1 | 0.020 |
Why?
|
Pyridines | 1 | 2006 | 98 | 0.020 |
Why?
|
Leg | 2 | 1976 | 83 | 0.020 |
Why?
|
Pyrazoles | 1 | 2006 | 74 | 0.020 |
Why?
|
American Heart Association | 1 | 2006 | 128 | 0.020 |
Why?
|
Sulfonamides | 1 | 2006 | 123 | 0.020 |
Why?
|
Bowen's Disease | 1 | 2004 | 1 | 0.010 |
Why?
|
Morals | 1 | 2005 | 22 | 0.010 |
Why?
|
Brazil | 2 | 1995 | 86 | 0.010 |
Why?
|
Radiotherapy | 1 | 1985 | 63 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 2004 | 104 | 0.010 |
Why?
|
Glycosylation | 1 | 2004 | 134 | 0.010 |
Why?
|
Ultraviolet Rays | 1 | 2004 | 125 | 0.010 |
Why?
|
Blood Pressure | 1 | 2006 | 522 | 0.010 |
Why?
|
Information Services | 1 | 2002 | 34 | 0.010 |
Why?
|
Social Perception | 1 | 2002 | 36 | 0.010 |
Why?
|
Body Mass Index | 1 | 2006 | 886 | 0.010 |
Why?
|
Boston | 1 | 2002 | 331 | 0.010 |
Why?
|
Biomarkers | 1 | 2006 | 1210 | 0.010 |
Why?
|
Learning | 1 | 2000 | 171 | 0.010 |
Why?
|
Sigmoid Neoplasms | 1 | 1978 | 2 | 0.010 |
Why?
|
Illinois | 1 | 1997 | 14 | 0.010 |
Why?
|
Skin Tests | 1 | 1997 | 21 | 0.010 |
Why?
|
Hospital Charges | 1 | 1997 | 23 | 0.010 |
Why?
|
Marijuana Smoking | 1 | 1997 | 16 | 0.010 |
Why?
|
World Health Organization | 1 | 1996 | 31 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1995 | 28 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 1976 | 118 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 1976 | 223 | 0.010 |
Why?
|
Scotland | 1 | 1995 | 7 | 0.010 |
Why?
|
Fever | 1 | 1995 | 63 | 0.010 |
Why?
|
Drug Resistance, Multiple | 1 | 1995 | 34 | 0.010 |
Why?
|
Graft Rejection | 1 | 1976 | 259 | 0.010 |
Why?
|
Self-Assessment | 1 | 1994 | 54 | 0.010 |
Why?
|
Personality Development | 1 | 1993 | 6 | 0.010 |
Why?
|
Child Abuse, Sexual | 1 | 1993 | 21 | 0.010 |
Why?
|
Child of Impaired Parents | 1 | 1993 | 28 | 0.010 |
Why?
|
Dangerous Behavior | 1 | 1993 | 22 | 0.010 |
Why?
|
Methods | 1 | 1972 | 39 | 0.010 |
Why?
|
Rehabilitation | 1 | 1991 | 6 | 0.010 |
Why?
|
Mycobacterium tuberculosis | 1 | 1995 | 383 | 0.010 |
Why?
|
Prosthesis Design | 1 | 1972 | 205 | 0.010 |
Why?
|
Contraception | 1 | 1992 | 64 | 0.010 |
Why?
|
Prenatal Care | 1 | 1993 | 180 | 0.010 |
Why?
|
Polymers | 1 | 1972 | 316 | 0.000 |
Why?
|
Aorta, Thoracic | 1 | 1988 | 78 | 0.000 |
Why?
|
Intermittent Claudication | 1 | 1988 | 48 | 0.000 |
Why?
|
Aorta | 1 | 1988 | 106 | 0.000 |
Why?
|
Hypothyroidism | 1 | 1968 | 39 | 0.000 |
Why?
|
Aortic Aneurysm | 1 | 1987 | 84 | 0.000 |
Why?
|